Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term pd [Pharmacology]. Found 15 abstracts

Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention. The Prostate. 2007 May;67(6):582-90.
Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-dependent Aurora A activation induces disassembly of the primary cilium.[see comment]. Cell. 2007 Jun 29;129(7):1351-63.
Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. International Journal of Gynecological Cancer. 2005 May;15 Suppl 1:12-7.
Cheng JD, Valianou M, Canutescu AA, Jaffe EK, Lee HO, Wang H, Lai JH, Bachovchin WW, Weiner LM. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Molecular Cancer Therapeutics. 2005 Mar;4(3):351-60.
Hayashi J, Stoyanova R, Seeger C. The transcriptome of HCV replicon expressing cell lines in the presence of alpha interferon. Virology. 2005 May 10;335(2):264-75.
Adams GP, Shaller CC, Dadachova E, Simmons HH, Horak EM, Tesfaye A, Klein-Szanto AJ, Marks JD, Brechbiel MW, Weiner LM. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.[see comment]. Cancer Research. 2004 Sep;64(17):6200-6.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Research. 2004 Feb;64(3):1181-9.
Borghaei H, Wallace SG, Schilder RJ. Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma. Clinical Lymphoma. 2004 Oct;5 Suppl 1:S16-21.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
Findlay VJ, Townsend DM, Saavedra JE, Buzard GS, Citro ML, Keefer LK, Ji X, Tew KD. Tumor cell responses to a novel glutathione S-transferase-activated nitric oxide-releasing prodrug. Molecular Pharmacology. 2004 May;65(5):1070-9.
Ile KE, Davis W, Boyd JT, Soulika AM, Tew KD. Identification of a novel first exon of the human ABCA2 transporter gene encoding a unique N-terminus. Biochimica et biophysica acta. 2004 Apr 16;1678(1):22-32.
Langer CJ. CT-2103: a novel macromolecular taxane with potential advantages compared with conventional taxanes. Clinical lung cancer. 2004 Dec;6 Suppl 2:S85-8.
Chen ZJ, Gate L, Davis W, Ile KE, Tew KD. Sensitivity and fidelity of DNA microarray improved withintegration of Amplified Differential Gene Expression (ADGE). BMC Genomics. 2003 Jul 14;4(1):28.
Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochemical pharmacology. 2002 Apr;63(7):1219-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term pd [Pharmacology]

pd [Pharmacology] me [Metabolism] de [Drug Effects] aa [Analogs & Derivatives] ge [Genetics] dt [Drug Therapy] ph [Physiology] ai [Antagonists & Inhibitors] Non-US Gov't Research Support tu [Therapeutic Use] Antineoplastic Agents 0 (Antineoplastic Agents) Cultured Tumor Cells Cell Division ch [Chemistry] Female Human Ovarian Neoplasms Cell Line Phenotype bi [Biosynthesis] Isoenzymes pa [Pathology] Mice Tumor Cell Line Phosphorylation 0 (Neoplasm Proteins) Non-US Gov't Support Protein-Serine-Threonine Kinases Yttrium Radioisotopes Transfection Gene Expression Profiling Enzyme Activation im [Immunology] EC 2-7-1-37 (Protein-Serine-Threonine Kinases) Apoptosis Monoclonal Antibodies Prostatic Neoplasms Cell Cycle SCID Mice 0 (Yttrium Radioisotopes) mt [Methods] 0 (Enzyme Inhibitors) Radioimmunotherapy en [Enzymology] rt [Radiotherapy] Male Enzyme Inhibitors Monoclonal) 0 (Antibodies Biological) 0 (Tumor Markers Multiple Drug Resistance ad [Administration & Dosage] Neoplasm Proteins US Gov't Support-PHS Oligonucleotide Array Sequence Analysis Molecular Models Antitumor Drug Screening Assays 0 (Isoenzymes) Biological Tumor Markers mammalian) 0 (MLH1 protein EC 1-14-99-1 (Prostaglandin-Endoperoxide Synthase) Sirolimus Cisplatin Cytotoxins Neoplasm) 0 (DNA Cell Proliferation 0 (ATP-Binding Cassette Transporters) 0 (Transcription Factor AP-1) Azo Compounds Xenograft Model Antitumor Assays Prodrugs Colorectal Neoplasms Base Sequence Second Primary Neoplasms EC 2-7-1 (aurora kinase) ri [Radionuclide Imaging] 0 (Anticarcinogenic Agents) Enzymologic Gene Expression Regulation 0 (Prodrugs) Estramustine Tissue Distribution Alternative Splicing 0 (Cyclins) Protein Kinases 2-diamine (N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1 Alkylating) 0 (Antineoplastic Agents CD20) 0 (Antigens Transcription Factors Viral Gene Expression Regulation EC 2-5-1-18 (Glutathione Transferase) 72025-60-6 (Leukotriene C4) 1-Phosphatidylinositol 3-Kinase 0 (Quinazolines) Signal Transducing Adaptor Proteins Signal Transducing) 0 (Adaptor Proteins Glioma Cytoplasmic and Nuclear) 0 (Receptors 0 (Taxoids) Research Design human) 0 (NEDD9 protein Glutathione Transferase 85622-93-1 (temozolomide) EC 2-1-1-63 (O(6)-Methylguanine-DNA Methyltransferase) 4-Aminobenzoic Acid 169590-42-5 (celecoxib) Protein p53 3T3 Cells Western Blotting erbB-2) EC 2-7-1-112 (Receptor 10102-43-9 (Nitric Oxide) 1406-18-4 (Vitamin E) Transcription Factor AP-1 Cytoplasmic and Nuclear Receptors 4-dinitro-5-(N-methyl-N-4-carboxyphenylamino)phenyl 0 (O(2)-(2 684-93-5 (Methylnitrosourea) Rats p38 Mitogen-Activated Protein Kinases Vitamin E Complementary DNA Inhibitors] 103882-84-4 (gemcitabine) 33069-62-4 (Paclitaxel) Fibroblasts 23214-92-8 (Doxorubicin) EC 2-5-1-18 (glutathione S-transferase pi) human) EC 3-6-1 (PMS2 protein EC 2-7-1 (mTOR protein) 0 (Sulfonamides) 0 (Nitric Oxide Donors) Flow Cytometry Comparative Study Lung Neoplasms 0 (polyglutamic acid-paclitaxel) 0 (DNA-Binding Proteins) st [Standards] Signal Transduction Proto-Oncogene Proteins Quality Control Epidermal Growth Factor) EC 2-7-1-112 (Receptor 56-45-1 (Serine) 25513-46-6 (Polyglutamic Acid) 0 (Immunotoxins) Non-Small-Cell Lung Carcinoma ae [Adverse Effects] Binding Sites 0 (NF-kappa B) Catalytic Domain 150-13-0 (4-Aminobenzoic Acid) Prostaglandin-Endoperoxide Synthase Glutathione
Last updated on Thursday, April 02, 2020